BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
92.16
+0.68 (0.74%)
At close: Jul 20, 2026, 4:00 PM EDT
92.16
0.00 (0.00%)
After-hours: Jul 20, 2026, 5:05 PM EDT
BioNTech SE Revenue
BioNTech SE had revenue of 148.50M EUR in the quarter ending March 31, 2026, a decrease of -39.24%. This brings the company's revenue in the last twelve months to 2.69B, up 4.82% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth.
Revenue (ttm)
2.69B EUR
Revenue Growth
+4.82%
P/S Ratio
7.22
Revenue / Employee
344,191 EUR
Employees
7,807
Market Cap
23.31B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | 162.80M | 5.63% |
| Dec 31, 2024 | 2.89B | -1.03B | -26.31% |
| Dec 31, 2023 | 3.92B | -13.39B | -77.33% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.74B |
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.44B |
| Alnylam Pharmaceuticals | 4.29B |
| Genmab | 3.90B |
| Royalty Pharma | 2.44B |
| Moderna | 2.23B |
| Ascendis Pharma | 998.25M |
BNTX News
- 12 days ago - BioNTech price target lowered to $119 from $126 at Morgan Stanley - TheFly
- 17 days ago - BioNTech held buyer talks over four German sites set to close, Handelsblatt reports - Reuters
- 4 weeks ago - Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO - Reuters
- 7 weeks ago - BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial - TheFly
- 7 weeks ago - Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewsWire
- 7 weeks ago - This Biotech's Cancer Portfolio Could End Its Rough Patch - Barrons
- 7 weeks ago - BioNTech upgraded to Buy from Neutral at UBS - TheFly
- 2 months ago - BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting - GlobeNewsWire